Compare · CDNA vs CNC
CDNA vs CNC
Side-by-side comparison of CareDx Inc. (CDNA) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDNA and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $34.83B, about 10.1x CDNA ($3.45B).
- CNC has been more active in the news (14 items in the past 4 weeks vs 6 for CDNA).
- CNC has more recent analyst coverage (25 ratings vs 20 for CDNA).
- Company
- CareDx Inc.
- Centene Corporation
- Price
- -
- -
- Market cap
- $3.45B
- $34.83B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2014
- News (4w)
- 6
- 14
- Recent ratings
- 20
- 25
CareDx Inc.
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors. CareDx, Inc. has a license agreement with Illumina, Inc. for the distribution, development and commercialization rights to NGS products and technologies; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest CDNA
- CareDx to Report Third Quarter 2026 Financial Results on October 29, 2026
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- SEC Form 4 filed by CareDx Inc.
- Amendment: CareDx Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets
- CFO & COO Kennedy Keith covered exercise/tax liability with 8,220 shares, decreasing direct ownership by 4% to 211,704 units (SEC Form 4) to satisfy withholding obligation
- Chief Commercial Officer Meng Jessica covered exercise/tax liability with 6,688 shares, decreasing direct ownership by 4% to 161,599 units (SEC Form 4) (for tax liability)
- Canaccord Genuity initiated coverage on CareDx with a new price target
Latest CNC
- Centene Corporation Demonstrates Commitment to CHOICE Arrangements through Benefit Programs in Indiana, Ohio and Oklahoma
- SEC Form 4 filed by Centene Corporation
- PA Health & Wellness Earns National Recognition Among Top Medicaid Health Plans for Second Consecutive Year
- Centene to Launch Nationwide Gold Card Program for Qualifying Providers
- SEC Form 8-K filed by Centene Corporation
- Ambetter Health Solutions and Marathon Health Expand Access to Primary Care for Members in Indiana and Missouri
- Wellcare Unveils 2027 Medicare Offerings Focused on Affordability and Integrated Care
- Director Tyler Lauren M was granted 482 shares, increasing direct ownership by 15% to 3,698 units (SEC Form 4)
- Director Tanji Kenneth was granted 603 shares, increasing direct ownership by 5% to 13,093 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 583 shares, increasing direct ownership by 2% to 25,796 units (SEC Form 4)